@misc{tilson_l._cost-effectiveness_2011,
	title = {Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in {Ireland}},
	abstract = {We evaluated the cost-effectiveness of universal infant rotavirus (RV) vaccination compared to current standard of care of "no vaccination". Two RV vaccines are currently licensed in Ireland: Rotarix and RotaTeq. A cohort model used in several European countries was adapted using Irish epidemiological, resource utilisation and cost data. The base case model considers the impact of Rotarix vaccination on health-related quality of life of children under five years old from a healthcare payer perspective. Other scenarios explored the use of RotaTeq, impact on one caregiver, on societal costs and on cases that do not seek medical attention. Cost was varied between the vaccine list price (100/course) in the base case and an assumed tender price (70/course). One-way and probabilistic sensitivity analyses were conducted. Implementing universal RV vaccination may prevent around 1970 GP visits, 3280 A\&E attendances and 2490 hospitalisations. A vaccination programme was estimated to cost approximately 6.54 million per year but 4.65 million of this would be offset by reducing healthcare resource use. The baseline ICER was 112,048/QALY and 72,736/QALY from the healthcare payer and societal perspective, respectively, falling to 68,896 and 43,916/QALY, respectively, if the impact on one caregiver was considered. If the price fell to 70 per course, universal RV vaccination would be cost saving under all scenarios. Results were sensitive to vaccination costs, incidence of RV infection and direct medical costs. Universal RV vaccination would not be cost-effective under base case assumptions. However, it could be cost-effective at a lower vaccine price or from a wider societal perspective. 2011 Elsevier Ltd.},
	journal = {Vaccine},
	author = {{Tilson L.} and {Jit M.} and {Schmitz S.} and {Walsh C.} and {Garvey P.} and {McKeown P.} and {Barry M.}},
	year = {2011},
	keywords = {*Rotavirus infection, *Rotavirus vaccine/dt [Drug Therapy], *Rotavirus vaccine/pe [Pharmacoeconomics], *cost effectiveness analysis, *gastroenteritis/dt [Drug Therapy], *gastroenteritis/pc [Prevention], *health program, *rotavirus gastroenteritis/dt [Drug Therapy], *rotavirus gastroenteritis/pc [Prevention], *vaccination, Hospitalization, Ireland, accident, article, caregiver, disease surveillance, drug cost, drug efficacy, drug safety, drug tolerability, emergency care, general practitioner, health care cost, health promotion, health service, home care, hospital infection, human, mortality, priority journal, quality of life, risk reduction, sensitivity analysis},
}

{"_id":"jk9DhJqXLkcZrrhuX","bibbaseid":"tilsonl-jitm-schmitzs-walshc-garveyp-mckeownp-barrym-costeffectivenessofuniversalrotavirusvaccinationinreducingrotavirusgastroenteritisinireland-2011","author_short":["Tilson L.","Jit M.","Schmitz S.","Walsh C.","Garvey P.","McKeown P.","Barry M."],"bibdata":{"bibtype":"misc","type":"misc","title":"Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland","abstract":"We evaluated the cost-effectiveness of universal infant rotavirus (RV) vaccination compared to current standard of care of \"no vaccination\". Two RV vaccines are currently licensed in Ireland: Rotarix and RotaTeq. A cohort model used in several European countries was adapted using Irish epidemiological, resource utilisation and cost data. The base case model considers the impact of Rotarix vaccination on health-related quality of life of children under five years old from a healthcare payer perspective. Other scenarios explored the use of RotaTeq, impact on one caregiver, on societal costs and on cases that do not seek medical attention. Cost was varied between the vaccine list price (100/course) in the base case and an assumed tender price (70/course). One-way and probabilistic sensitivity analyses were conducted. Implementing universal RV vaccination may prevent around 1970 GP visits, 3280 A&E attendances and 2490 hospitalisations. A vaccination programme was estimated to cost approximately 6.54 million per year but 4.65 million of this would be offset by reducing healthcare resource use. The baseline ICER was 112,048/QALY and 72,736/QALY from the healthcare payer and societal perspective, respectively, falling to 68,896 and 43,916/QALY, respectively, if the impact on one caregiver was considered. If the price fell to 70 per course, universal RV vaccination would be cost saving under all scenarios. Results were sensitive to vaccination costs, incidence of RV infection and direct medical costs. Universal RV vaccination would not be cost-effective under base case assumptions. However, it could be cost-effective at a lower vaccine price or from a wider societal perspective. 2011 Elsevier Ltd.","journal":"Vaccine","author":[{"firstnames":[],"propositions":[],"lastnames":["Tilson L."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Jit M."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Schmitz S."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Walsh C."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Garvey P."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["McKeown P."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Barry M."],"suffixes":[]}],"year":"2011","keywords":"*Rotavirus infection, *Rotavirus vaccine/dt [Drug Therapy], *Rotavirus vaccine/pe [Pharmacoeconomics], *cost effectiveness analysis, *gastroenteritis/dt [Drug Therapy], *gastroenteritis/pc [Prevention], *health program, *rotavirus gastroenteritis/dt [Drug Therapy], *rotavirus gastroenteritis/pc [Prevention], *vaccination, Hospitalization, Ireland, accident, article, caregiver, disease surveillance, drug cost, drug efficacy, drug safety, drug tolerability, emergency care, general practitioner, health care cost, health promotion, health service, home care, hospital infection, human, mortality, priority journal, quality of life, risk reduction, sensitivity analysis","bibtex":"@misc{tilson_l._cost-effectiveness_2011,\n\ttitle = {Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in {Ireland}},\n\tabstract = {We evaluated the cost-effectiveness of universal infant rotavirus (RV) vaccination compared to current standard of care of \"no vaccination\". Two RV vaccines are currently licensed in Ireland: Rotarix and RotaTeq. A cohort model used in several European countries was adapted using Irish epidemiological, resource utilisation and cost data. The base case model considers the impact of Rotarix vaccination on health-related quality of life of children under five years old from a healthcare payer perspective. Other scenarios explored the use of RotaTeq, impact on one caregiver, on societal costs and on cases that do not seek medical attention. Cost was varied between the vaccine list price (100/course) in the base case and an assumed tender price (70/course). One-way and probabilistic sensitivity analyses were conducted. Implementing universal RV vaccination may prevent around 1970 GP visits, 3280 A\\&E attendances and 2490 hospitalisations. A vaccination programme was estimated to cost approximately 6.54 million per year but 4.65 million of this would be offset by reducing healthcare resource use. The baseline ICER was 112,048/QALY and 72,736/QALY from the healthcare payer and societal perspective, respectively, falling to 68,896 and 43,916/QALY, respectively, if the impact on one caregiver was considered. If the price fell to 70 per course, universal RV vaccination would be cost saving under all scenarios. Results were sensitive to vaccination costs, incidence of RV infection and direct medical costs. Universal RV vaccination would not be cost-effective under base case assumptions. However, it could be cost-effective at a lower vaccine price or from a wider societal perspective. 2011 Elsevier Ltd.},\n\tjournal = {Vaccine},\n\tauthor = {{Tilson L.} and {Jit M.} and {Schmitz S.} and {Walsh C.} and {Garvey P.} and {McKeown P.} and {Barry M.}},\n\tyear = {2011},\n\tkeywords = {*Rotavirus infection, *Rotavirus vaccine/dt [Drug Therapy], *Rotavirus vaccine/pe [Pharmacoeconomics], *cost effectiveness analysis, *gastroenteritis/dt [Drug Therapy], *gastroenteritis/pc [Prevention], *health program, *rotavirus gastroenteritis/dt [Drug Therapy], *rotavirus gastroenteritis/pc [Prevention], *vaccination, Hospitalization, Ireland, accident, article, caregiver, disease surveillance, drug cost, drug efficacy, drug safety, drug tolerability, emergency care, general practitioner, health care cost, health promotion, health service, home care, hospital infection, human, mortality, priority journal, quality of life, risk reduction, sensitivity analysis},\n}\n\n","author_short":["Tilson L.","Jit M.","Schmitz S.","Walsh C.","Garvey P.","McKeown P.","Barry M."],"key":"tilson_l._cost-effectiveness_2011","id":"tilson_l._cost-effectiveness_2011","bibbaseid":"tilsonl-jitm-schmitzs-walshc-garveyp-mckeownp-barrym-costeffectivenessofuniversalrotavirusvaccinationinreducingrotavirusgastroenteritisinireland-2011","role":"author","urls":{},"keyword":["*Rotavirus infection","*Rotavirus vaccine/dt [Drug Therapy]","*Rotavirus vaccine/pe [Pharmacoeconomics]","*cost effectiveness analysis","*gastroenteritis/dt [Drug Therapy]","*gastroenteritis/pc [Prevention]","*health program","*rotavirus gastroenteritis/dt [Drug Therapy]","*rotavirus gastroenteritis/pc [Prevention]","*vaccination","Hospitalization","Ireland","accident","article","caregiver","disease surveillance","drug cost","drug efficacy","drug safety","drug tolerability","emergency care","general practitioner","health care cost","health promotion","health service","home care","hospital infection","human","mortality","priority journal","quality of life","risk reduction","sensitivity analysis"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"misc","biburl":"https://bibbase.org/zotero/robin.marlow","dataSources":["ix72eqAAMGCuupBaz"],"keywords":["*rotavirus infection","*rotavirus vaccine/dt [drug therapy]","*rotavirus vaccine/pe [pharmacoeconomics]","*cost effectiveness analysis","*gastroenteritis/dt [drug therapy]","*gastroenteritis/pc [prevention]","*health program","*rotavirus gastroenteritis/dt [drug therapy]","*rotavirus gastroenteritis/pc [prevention]","*vaccination","hospitalization","ireland","accident","article","caregiver","disease surveillance","drug cost","drug efficacy","drug safety","drug tolerability","emergency care","general practitioner","health care cost","health promotion","health service","home care","hospital infection","human","mortality","priority journal","quality of life","risk reduction","sensitivity analysis"],"search_terms":["cost","effectiveness","universal","rotavirus","vaccination","reducing","rotavirus","gastroenteritis","ireland","tilson l.","jit m.","schmitz s.","walsh c.","garvey p.","mckeown p.","barry m."],"title":"Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland","year":2011}